Business Context and Reporting Period
This Form 8-K Current Report was filed by Processa Pharmaceuticals, Inc. on September 18, 2023. The filing addresses corporate governance updates and regulatory compliance status regarding the company's listing on the Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate events rather than financial performance data.
Material Changes and Corporate Actions
Nasdaq Listing Compliance (Item 3.01)
- Deficiency: The company previously failed to meet the Nasdaq minimum bid price requirement of $1.00 per share for 30 consecutive business days.
- Grace Period: On September 19, 2023, Nasdaq granted a second 180-day grace period, extending until March 18, 2024, to regain compliance.
- Compliance Path: The company intends to cure the deficiency, potentially through a reverse stock split, if the stock price does not naturally recover to at least $1.00 for 10 consecutive business days.
- Current Status: The stock remains listed and traded on the Nasdaq Capital Market pending compliance.
Amendment to Bylaws (Item 5.03)
On September 18, 2023, the Board of Directors adopted Amended and Restated Bylaws effective immediately. Key changes include:
- Voting Standards: Routine matters now require a majority of votes cast (abstentions have no effect).
- Stockholder Action: Stockholders may act by written consent following specified procedures.
- Board Composition: The Board can change the number of directors via resolution; stockholders cannot fill Board vacancies.
- Director Removal: Directors may only be removed for cause by a 66% vote of stockholders; removal without cause is no longer permitted.
- Indemnification: Exceptions to indemnification previously in the Bylaws were removed.
- Meetings and Jurisdiction: The Board may hold electronic stockholder meetings. Derivative actions and fiduciary breach claims must be filed exclusively in the Court of Chancery in Delaware.
Guidance, Outlook, and Risks
The filing does not contain financial guidance or management commentary on future operational outlook. The primary risk disclosed is the potential delisting from Nasdaq if the company fails to regain compliance with the $1.00 minimum bid price requirement by March 18, 2024.
Investor Verification Checklist
- Verify the current trading price of PCSA to assess the likelihood of meeting the $1.00 bid price requirement without a reverse stock split.
- Monitor future filings for the formal proposal and shareholder vote required to effect a reverse stock split.
- Review the full text of the Amended and Restated Bylaws (Exhibit 3.1) for detailed governance implications.
- Confirm the company's cash position in subsequent filings (10-Q or 10-K) to evaluate its ability to fund operations during the grace period.